Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03266653 · ClinicalTrials.gov registry record · Phase 2
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
A Phase 2 study of Epstein-Barr Virus Infections and Primary Immune Deficiency Disorder, sponsored by New York Medical College.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 8
- Study locations
NCT03266653 is a Phase 2 study of Epstein-Barr Virus Infections and Primary Immune Deficiency Disorder that is actively recruiting participants, run by New York Medical College. The registered enrollment target is 20 participants, below the 246-participant average among 6 other Epstein-Barr Virus Infections trials with a reported enrollment target (92% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT03266653, a Phase 2 study of Epstein-Barr Virus Infections and Primary Immune Deficiency Disorder, is actively recruiting participants, sponsored by New York Medical College.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 8
- Study locations
Study Summary
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Conditions Studied
Interventions
- DRUG cytotoxic t-lymphocytes
Study Locations (8)
California
- Children's Hosptial Los Angeles - Los Angeles
- University of California San Francisco - San Francisco
Maryland
- Johns Hopkins - Baltimore
Missouri
- Washington University - St Louis
New York
- New York Medical College - Valhalla
Ohio
- Nationwide Children's Hosptial - Columbus
Pennsylvania
- Children's Hospital of Pennsylvania - Philadelphia
Wisconsin
- Medical College of Wisconsin/Children's Hospital of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-07-07 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03266653
The ClinicalTrials.gov registry entry for NCT03266653 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 6 other Epstein-Barr Virus Infections trials with a reported enrollment target (92% lower). The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epstein-Barr Virus Infections appearing as the primary indexed condition, and to 1 intervention - of which cytotoxic t-lymphocytes is the first listed.
NCT03266653 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT03266653 about?
NCT03266653 is a clinical study titled "EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection". Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (Allo...
What is the current status of trial NCT03266653?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-07-07. Estimated completion is 2027-12-31.
What conditions does trial NCT03266653 study?
This clinical trial studies the following conditions: Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder.
What interventions are being tested in trial NCT03266653?
The interventions under investigation include: cytotoxic t-lymphocytes (DRUG).
Who is sponsoring clinical trial NCT03266653?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03266653 being conducted?
This trial has 8 study locations across California, Maryland, Missouri, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epstein-Barr Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
RECRUITING · Phase 2
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
COMPLETED · Phase 1
-
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
COMPLETED
Explore more on PlainTrial
Epstein-Barr Virus Infections
All registered trials for this condition
Primary Immune Deficiency Disorder
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.